



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/808,758	03/24/2004	Daniel J. Von Seggern	5410-006 (312552-24)	6593

28213 7590 10/08/2008
DLA PIPER LLP (US)
4365 EXECUTIVE DRIVE
SUITE 1100
SAN DIEGO, CA 92121-2133

EXAMINER

BLUMEL, BENJAMIN P

ART UNIT	PAPER NUMBER
----------	--------------

1648

MAIL DATE	DELIVERY MODE
-----------	---------------

10/08/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address : COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10808758	3/24/2004	SEGGERN, DANIEL J. VON	5410-006 (312552-24)

DLA PIPER LLP (US)
4365 EXECUTIVE DRIVE
SUITE 1100
SAN DIEGO, CA 92121-2133

EXAMINER

BENJAMIN P. BLUMEL

ART UNIT	PAPER
----------	-------

1648	20081003
------	----------

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed on July 2, 2008 is not fully responsive to the prior Office action because of the following omission(s) or matter(s): an election of adenovirus serotype 37 does not satisfy the requirement for an election of a species as required by the Office action for a specific adenovirus group D serotype. Applicants elected invention I, however, adenovirus 37 is not mentioned in any of the claims relating to invention I (i.e., claims 1-28 and 34-40). In order to be fully compliant with the election of species requirement, as stated on page 6, lines 5 and 6 of the prior Office action, applicants must elect a specific species serotype recited by the claims of invention I. For example, invention I includes the adenovirus serotypes of 8-10, 13, 15, 17, 19a, 19b, 20, 22-30, 32, 33, 36, 38, 39 and 42-49 (see claim 1), but not serotype 37. The applicants are notified that any claims not reading on the elected invention/species will be withdrawn from consideration. See 37 CFR 1.111. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

/Stacy B. Chen/
Primary Examiner, Art Unit 1648

/Benjamin P. Blumel/
AU 1648 Patent Examiner